Simon Thomas, CEO & Co-Founder, Paragraf

Paragraf is a Cambridge University spinout pioneering the commercial production of graphene-based electronic devices.

Since its inception, the company has focused on transforming graphene from a promising laboratory material into commercially viable products capable of delivering next-generation performance across a range of industries.

In this episode of Meet the Portfolio, CEO Simon Thomas shares the story behind Paragraf, from its foundations in university research to its development as a leading advanced materials company.

The interview explores the potential of graphene, the challenges associated with scaling deeptech manufacturing, and how Paragraf is bringing innovative products to market through its unique manufacturing approach.

Watch the full video to hear more about the company’s journey from breakthrough science to commercial application, and the opportunities that lie ahead for graphene technologies.

To find out more about Paragraf, visit their website or our portfolio page here.

The products shown on this website will place your capital at risk and investors may not get back the full amount invested. Past performance may not be repeated and is not indicative of future results.

Parkwalk funds invest in smaller and unquoted companies which carry a higher risk than many other forms of investment. There is no guarantee that target returns will be achieved. There is no liquid market for shares in unquoted companies and there can be difficulties, in valuing and disposing of investments in such companies. Tax reliefs will depend on the investors’ individual circumstance and are subject to change.

Parkwalk does not provide investment or tax advice, and the information on this website should not be construed as such. Parkwalk recommends investors seek advice from a regulated financial adviser that specialises in EIS fund investments before making an investment decision. An investment into any of the funds managed by Parkwalk may only be made on the basis of the information set out in the Information Memorandum and Key Information Document.

The information on this website is directed at United Kingdom residents only. Please confirm you have read this warning and are happy to proceed.